STOCK TITAN

InMed Pharmaceuticals director holds 27,868 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
3

Rhea-AI Filing Summary

InMed Pharmaceuticals Inc. director Michelle Patricia Pernice reported direct holdings of 27,868 common shares following the merger effective November 6, 2026. The shares were received in exchange for her Pre-Merger Mentari common shares. Of the reported shares, 19,740 remain subject to forfeiture restrictions and vest in equal monthly installments through August 13, 2029, subject to continued service on each vesting date.

Insider Pernice Michelle Patricia
Role Director
Type Security Shares Price Value
Holding Common Stock F1, F2 -- -- --
Holdings: Common Stock — 27,868 shares (Direct)
Footnotes (2)
  1. F1. Effective as of November 6, 2026 (the "Effective Time"), (i) Indigo Merger Sub Corp., a wholly owned subsidiary of Mentari Therapeutics, Inc. (formerly known as InMed Pharmaceuticals Inc.), a Nevada corporation (the "Issuer"), merged with and into Mentari Therapeutics, Inc., a Delaware corporation ("Pre-Merger Mentari"), with Pre-Merger Mentari continuing as a wholly owned subsidiary of the Issuer and the surviving corporation of the merger (the "First Merger"), and (ii) immediately thereafter, Pre-Merger Mentari merged with and into Indigo Merger Sub II, LLC, a second wholly owned subsidiary of the Issuer ("Second Merger Sub"), with Second Merger Sub being the surviving entity of the merger under the name Mentari Therapeutics Operating Company LLC (the "Second Merger" and, together with the First Merger, the "Merger").
  2. F2. Represents shares of the Issuer's common stock received by the Reporting Person in the Merger in exchange for the shares of Pre-Merger Mentari's common stock held by the Reporting Person prior to the Merger. Each share of Pre-Merger Mentari's restricted common stock held at the Effective Time was exchanged for 0.20065 restricted shares of the Issuer's common stock. Of these shares of common stock, 19,740 remain subject to forfeiture restrictions and vest in equal monthly installments through August 13, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Direct common shares held 27,868 shares Reported following the merger effective November 6, 2026
Shares subject to forfeiture restrictions 19,740 shares Vest in equal monthly installments through August 13, 2029, subject to continued service
Merger exchange ratio 0.20065 restricted shares Each Pre-Merger Mentari restricted common share held at the Effective Time was exchanged for this number of issuer restricted common shares
restricted common stock technical
"Pre-Merger Mentari's restricted common stock held at the Effective Time"
Restricted common stock is company shares that carry limits on selling or transferring for a set period or until certain conditions are met, like time-based vesting or regulatory clearance. Think of them as shares in a locked box that gradually open; they can become freely tradable later but initially reduce the number of shares available on the market. Investors watch restricted stock because its eventual release can change a company’s share supply, affect stock price, and influence control and dilution.
forfeiture restrictions technical
"19,740 remain subject to forfeiture restrictions"
wholly owned subsidiary technical
"Pre-Merger Mentari continuing as a wholly owned subsidiary of the Issuer"
A wholly owned subsidiary is a company whose entire ownership is held by another company (the parent), so the parent controls decisions, operations, and finances. Think of it as a fully controlled branch that runs as its own legal entity but whose results flow straight into the parent’s financial statements; investors watch these structures because they affect consolidated revenue, risk exposure, and how profits, liabilities, and cash flow are allocated across the corporate group.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many INM shares did Michelle Patricia Pernice report holding?

Michelle Patricia Pernice reported directly holding 27,868 shares of common stock following the merger effective November 6, 2026.

How many of Michelle Patricia Pernice’s INM shares are restricted?

19,740 shares remain subject to forfeiture restrictions and vest in equal monthly installments through August 13, 2029, subject to her continued service on each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Pernice Michelle Patricia

(Last)(First)(Middle)
C/O MENTARI THERAPEUTICS, INC.
221 CRESCENT ST., BUILDING 23, SUITE 105

(Street)
WALTHAM MASSACHUSETTS 02453

(City)(State)(Zip)

UNITED STATES

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
11/06/2026
3. Issuer Name and Ticker or Trading Symbol
InMed Pharmaceuticals Inc. [ MTRI ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock27,868(1)(2)D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Effective as of November 6, 2026 (the "Effective Time"), (i) Indigo Merger Sub Corp., a wholly owned subsidiary of Mentari Therapeutics, Inc. (formerly known as InMed Pharmaceuticals Inc.), a Nevada corporation (the "Issuer"), merged with and into Mentari Therapeutics, Inc., a Delaware corporation ("Pre-Merger Mentari"), with Pre-Merger Mentari continuing as a wholly owned subsidiary of the Issuer and the surviving corporation of the merger (the "First Merger"), and (ii) immediately thereafter, Pre-Merger Mentari merged with and into Indigo Merger Sub II, LLC, a second wholly owned subsidiary of the Issuer ("Second Merger Sub"), with Second Merger Sub being the surviving entity of the merger under the name Mentari Therapeutics Operating Company LLC (the "Second Merger" and, together with the First Merger, the "Merger").
2. Represents shares of the Issuer's common stock received by the Reporting Person in the Merger in exchange for the shares of Pre-Merger Mentari's common stock held by the Reporting Person prior to the Merger. Each share of Pre-Merger Mentari's restricted common stock held at the Effective Time was exchanged for 0.20065 restricted shares of the Issuer's common stock. Of these shares of common stock, 19,740 remain subject to forfeiture restrictions and vest in equal monthly installments through August 13, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Remarks:
Exhibit 24 - Power of Attorney
/s/ Jerad G. Seurer, as attorney-in-fact for Michelle Pernice11/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Keep reading